Table 2.
Individual patients' information and concomitant genomic alterations.
| No | Sex | Age | Cancer type | Histology | Strong fusion | SNV/indel |
|---|---|---|---|---|---|---|
| 1 | M | 48 | CRC | M/D ADC | TPM3 ⟶ NTRK1 | KRAS G12V |
| 2 | F | 74 | CRC | M/D ADC | TPM3 ⟶ NTRK1, | |
| 3 | F | 78 | STS | Angiosarcoma | PEAR1 ⟶ NTRK1 | |
| 4 | M | 68 | BTC | M/D ADC | FGFR3 ⟶ TACC3, | |
| 5 | M | 58 | GC | M/D ADC | FGFR3 ⟶ TACC3, | |
| 6 | F | 53 | CRC | M/D ADC | NCOA4 ⟶ RET | |
| 7 | F | 32 | GC | P/D ADC | INTERGENIC ⟶ CSMD1 ⟶ RAF1 | |
| 8 | F | 35 | Melanoma | Skin melanoma | MAPRE2 ⟶ RAF1 | |
| 9 | M | 58 | STS | Retroperitoneal leiomyosarcoma | IGH-AS ⟶ RAF1, AXL ⟶ LOC440300 |
|
| 10 | F | 60 | Pancreas cancer | M/D ADC | IQSEC1 ⟶ RAF1 | KRAS G12D |
| 11 | M | 56 | CRC | SRCC | MAP7D1 ⟶ EGFR | KRAS G13D PIK3CA H1047R |
| 12 | M | 57 | CRC | W/D ADC | LACE1 ⟶ ROS1 | KRAS G12A |
| 13 | M | 80 | BTC | P/D ADC | SP6 ⟶ ALK, THADA ⟶ VPS36 |
|
| 14 | M | 65 | CRC | W/D ADC | AXL ⟶ ALK | |
| 15 | M | 66 | GC | P/D ADC | AXL ⟶ IGH-AS | |
| 16 | M | 56 | BTC | M/D ADC | FGFR2 ⟶ NRAP | |
| 17 | M | 56 | GC | SRCC | CLDN18 ⟶ ARHGAP26 | |
| 18 | M | 47 | GC | P/D ADC | CLDN18 ⟶ ARHGAP26 | |
| 19 | M | 67 | BTC | ADC | BRAF ⟶ INTERGENIC ⟶ PTMA | |
| 20 | M | 51 | STS | Extraskeletal myxoid chondrosarcoma | EWSR1 ⟶ NR4A3, BRAF ⟶ UNALIGNED ⟶ LOC100996643 |
|
| 21 | M | 50 | STS | Liver leiomyosarcoma | CTBP2 ⟶ NOTCH2 | |
| 22 | F | 49 | STS | Uterine leiomyosarcoma | ENO2 ⟶ ETV4 | |
| 23 | M | 56 | STS | Retroperitoneal Malignant SFT |
GNA13 ⟶ PRKCA | |
| 24 | F | 61 | BTC | P/D ADC | LOC100506217 ⟶ RELA | |
| 25 | M | 52 | CRC | M/D ADC | ESR1 ⟶ KIAA1731 |
CRC: colorectal cancer; GC: gastric cancer; BTC: biliary tract cancer; STS: soft tissue sarcoma; W/D ADC: well-differentiated adenocarcinoma; M/D ADC: moderately differentiated adenocarcinoma; P/D ADC: poorly differentiated adenocarcinoma; SRCC: signet ring cell carcinoma.